A parallel signal-transduction pathway for eotaxin- and interleukin-5-induced eosinophil shape change

被引:27
作者
Choi, EN
Choi, MK
Park, CS
Chung, IY
机构
[1] Hanyang Univ, Dept Biochem & Mol Biol, Ansan 425791, Kyunggi Do, South Korea
[2] Soonchunhyang Univ Hosp, Div Allergy & Resp Med, Bucheon, South Korea
[3] Soonchunhyang Univ Hosp, Dept Internal Med, Bucheon, South Korea
关键词
D O I
10.1046/j.1365-2567.2003.01565.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Interleukin-5 (IL-5) and eotaxin are the most important cytokines/chemokines responsible for regulating eosinophil locomotion and are known to play a co-operative role in the selective recruitment of eosinophils to inflamed tissues. Following exposure to chemoattractants, eosinophils undergo a series of events, including reorganization of actin filaments and subsequent rapid shape changes, culminating in chemotaxis. In this study we examined the signalling pathways for eosinophil shape change regulated by eotaxin and IL-5, primarily using a gated autofluorescence/forward-scatter assay. Eotaxin and IL-5 were able to elicit shape change with peaks at 10 and 60 min, respectively, and IL-5 triggered the shape change more efficiently than eotaxin. The pharmacological inhibitors of mitogen-activated protein kinase (MAP kinase) and p38 blocked both eotaxin- and IL-5-induced eosinophil shape change in a dose-dependent manner. In addition, depletion of intracellular Ca2+ and inhibition of protein kinase A (PKA) strongly reduced eosinophil shape change. In contrast, even when used at high concentrations, protein tyrosine kinase (PTK) inhibitors caused only a slight reduction in the ability to change shape. However, treatment with protein kinase C (PKC) inhibitors, such as GF109203X and staurosporine, resulted in a striking inhibition of eosinophil shape change by IL-5, but not eotaxin. Data from the inhibition of activation and chemotaxis of the extracellular signal-regulated kinases (ERK1/2) by the PKC inhibitors were also consistent with findings from the experiments on shape change. Collectively, two eosinophil-selective cytokines/chemokines probably regulate eosinophil shape change via a largely overlapping signalling pathway, with involvement of PKC restricted to the IL-5 signal alone.
引用
收藏
页码:245 / 256
页数:12
相关论文
共 58 条
[1]   The differential role of extracellular signal-regulated kinases and p38 mitogen-activated protein kinase in eosinophil functions [J].
Adachi, T ;
Choudhury, BK ;
Stafford, S ;
Sur, S ;
Alam, R .
JOURNAL OF IMMUNOLOGY, 2000, 165 (04) :2198-2204
[2]   PD-098059 IS A SPECIFIC INHIBITOR OF THE ACTIVATION OF MITOGEN-ACTIVATED PROTEIN-KINASE KINASE IN-VITRO AND IN-VIVO [J].
ALESSI, DR ;
CUENDA, A ;
COHEN, P ;
DUDLEY, DT ;
SALTIEL, AR .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (46) :27489-27494
[3]   Regulation of human eosinophil NADPH oxidase activity:: A central role for PKCδ [J].
Bankers-Fulbright, JL ;
Kita, H ;
Gleich, GJ ;
O'Grady, SM .
JOURNAL OF CELLULAR PHYSIOLOGY, 2001, 189 (03) :306-315
[4]   ERK1 and ERK2 activation by chemotactic factors in human eosinophils is interleukin 5-dependent and contributes to leukotriene C4 biosynthesis [J].
Bates, ME ;
Green, VL ;
Bertics, PJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (15) :10968-10975
[5]  
Boehme SA, 1999, J IMMUNOL, V163, P1611
[6]   EOSINOPHILIC INFLAMMATION IN ASTHMA [J].
BOUSQUET, J ;
CHANEZ, P ;
LACOSTE, JY ;
BARNEON, G ;
GHAVANIAN, N ;
ENANDER, I ;
VENGE, P ;
AHLSTEDT, S ;
SIMONYLAFONTAINE, J ;
GODARD, P ;
MICHEL, FB .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 323 (15) :1033-1039
[7]  
Bracke M, 1998, J IMMUNOL, V161, P6768
[8]  
CLUTTERBUCK EJ, 1989, BLOOD, V73, P1504
[9]   Analysis of signal transduction pathways in human eosinophils activated by chemoattractants and the T-helper 2-derived cytokines interleukin-4 and interleukin-5 [J].
Coffer, PJ ;
Schweizer, RC ;
Dubois, GR ;
Maikoe, T ;
Lammers, JWJ ;
Koenderman, L .
BLOOD, 1998, 91 (07) :2547-2557
[10]   COOPERATION BETWEEN INTERLEUKIN-5 AND THE CHEMOKINE EOTAXIN TO INDUCE EOSINOPHIL ACCUMULATION IN-VIVO [J].
COLLINS, PD ;
MARLEAU, S ;
GRIFFITHSJOHNSON, DA ;
JOSE, PJ ;
WILLIAMS, TJ .
JOURNAL OF EXPERIMENTAL MEDICINE, 1995, 182 (04) :1169-1174